The mTOR inhibitor everolimus demonstrates efficacy in SSA-refractory pulmonary or gastroenteropancreatic NENs with median PFS of 16.4 months versus 11.3 months for placebo, though requires monitoring for pneumonitis (13% incidence) (42, 43). Here, MTOR is linked to pneumonitis.